Skip to main content
    I

    Iradimed Co (IRMD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $84.84
    -0.51 (-0.60%)

    Market Cap: $1.09B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Iradimed Co (IRMD) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Iradimed (IRMD) trades at 43.5x trailing earnings and 12.1x sales. Its P/E of 43.5x is above its 5-year median of 34.6x. Its forward P/E is 35.6x. The median P/E across 8 similar companies is 13.6x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 22.2% higher over the next year. Its free cash flow yield is 2.4%.

    MultipleValue
    P/E (trailing)43.5x
    Forward P/E35.6x
    Price to sales12.1x
    Price to book10.2x
    EV/EBITDA31.2x
    Price to FCF41.7x
    EV/FCF39.3x
    PEG4.5
    FCF yield2.4%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 21.8% above 35.7x, its P/S is 37.5% above 8.8x and its P/B is 52.2% above 6.7x.

    MultipleCurrent5-year median10-year median
    P/E43.5x34.6x35.7x
    P/S12.1x9.4x8.8x
    P/B10.2x8.0x6.7x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 15.9x in 2016 to 72.1x in 2017.

    Year endPriceP/EP/SP/B
    2025$97.2850.7x14.8x13.2x
    2024$55.0034.2x9.5x8.1x
    2023$47.4732.1x9.1x8.5x
    2022$28.2926.0x6.7x4.8x
    2021$46.2155.7x13.7x8.1x
    2020$22.8055.6x8.8x4.6x
    2019$23.3827.2x7.0x5.2x
    2018$24.4645.3x8.9x7.1x
    2017$15.1572.1x7.2x5.4x
    2016$11.1015.9x3.8x4.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About IRMD

    What is IRMD's forward P/E ratio?

    Iradimed has a forward P/E ratio of 35.6x.

    Is IRMD stock overvalued?

    GNG's valuation label for IRMD is Fairly valued. Its P/E of 43.5x compares with a median of 13.6x across 8 similar companies.

    What is IRMD's price to sales ratio?

    Iradimed has a price to sales ratio of 12.1x.

    What is Iradimed's average P/E ratio over 5 years?

    Iradimed's median P/E over the last 5 years is 34.6x, from 60 month-end values through Oct 2026.

    What is IRMD's PEG ratio?

    Iradimed has a PEG ratio of 4.5.